Drotaverine produced hypoglycaemia and hypolipidemia in STZ/NA induced diabetic rats through inhibition of phosphodiesterase IV enzyme

The current investigation was undertaken to assess the possible anti-diabetic effect of drotaverine in diabetic rats. Hyperglycaemia was induced with single intraperitoneal dose of streptozotocin (STZ) and nicotinamide (NA) at 60 and 110 mg/kg, respectively. Treatment with drotaverine (4 and 8 mg/kg p.o.) and standard (metformin) was started on fourth day after confirmation of hyperglycaemia up to 21 days. Blood glucose level (BGL) was checked on weekly basis with glucometer; ECG and HRV was carried out to monitor the cardio toxicity. Animals were sacrificed under mild anaesthesia by cervical dislocation. Antioxidant and liver parameters were measured. Administration of drotaverine up to 21 days significantly reduced the BGL in treatment groups. Drotaverine caused no cardio toxicity in treated animals as evidenced by ECG and HRV. Restoration of antioxidant and liver enzymes level indicates absence of hepatotoxicity. Such findings we suggest that drotaverine possess a very good anti-diabetic potential.